883
Views
12
CrossRef citations to date
0
Altmetric
Research Paper

In human retinoblastoma Y79 cells okadaic acid–parthenolide co-treatment induces synergistic apoptotic effects, with PTEN as a key player

, , , , , , , & show all
Pages 922-931 | Received 08 May 2013, Accepted 29 Jul 2013, Published online: 12 Aug 2013

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Radhika Manukonda, Revu VL Narayana, Swathi Kaliki, Dilip K Mishra & Geeta K Vemuganti. (2022) Emerging therapeutic targets for retinoblastoma. Expert Opinion on Therapeutic Targets 26:11, pages 937-947.
Read now

Articles from other publishers (11)

Courtney R. Croley, Joshua Pumarol, Blake E. Delgadillo, Andrew C. Cook, Faith Day, Tea Kaceli, Caroline C. Ward, Imran Husain, Ali Husain, Sabyasachi Banerjee & Anupam Bishayee. (2023) Signaling pathways driving ocular malignancies and their targeting by bioactive phytochemicals. Pharmacology & Therapeutics 248, pages 108479.
Crossref
Gabriel Mbuta Tchivelekete, Mohammad Almarhoun, Yanqun Cao, Xinzhi Zhou, Patricia E. Martin & Xinhua Shu. (2022) Evaluation of okadaic acid toxicity in human retinal cells and zebrafish retinas. Toxicology 473, pages 153209.
Crossref
María Belen Cancela, Santiago Zugbi, Ursula Winter, Ana Laura Martinez, Claudia Sampor, Mariana Sgroi, Jasmine H. Francis, Ralph Garippa, David H. Abramson, Guillermo Chantada & Paula Schaiquevich. (2020) A decision process for drug discovery in retinoblastoma. Investigational New Drugs 39:2, pages 426-441.
Crossref
Tareq Abu-Izneid, Abdur Rauf, Mohammad Ali Shariati, Anees Ahmed Khalil, Muhammad Imran, Maksim Rebezov, Md. Sahab Uddin, Mohamad Fawzi Mahomoodally & Kannan R.R. Rengasamy. (2020) Sesquiterpenes and their derivatives-natural anticancer compounds: An update. Pharmacological Research 161, pages 105165.
Crossref
Malgorzata Sztiller-Sikorska & Malgorzata Czyz. (2020) Parthenolide as Cooperating Agent for Anti-Cancer Treatment of Various Malignancies. Pharmaceuticals 13:8, pages 194.
Crossref
Yongliang Cao, Fei Xia, Ping Wang & Meng Gao. (2018) MicroRNA‑93‑5p promotes the progression of human retinoblastoma by regulating the PTEN/PI3K/AKT signaling pathway. Molecular Medicine Reports.
Crossref
Hashem Alsaab, Rami Alzhrani, Prashant Kesharwani, Samaresh Sau, Sai Boddu & Arun Iyer. (2017) Folate Decorated Nanomicelles Loaded with a Potent Curcumin Analogue for Targeting Retinoblastoma. Pharmaceutics 9:4, pages 15.
Crossref
Daniela Massihnia, Alessandro Perez, Viviana Bazan, Giuseppe Bronte, Marta Castiglia, Daniele Fanale, Nadia Barraco, Antonina Cangemi, Florinda Di Piazza, Valentina Calò, Sergio Rizzo, Giuseppe Cicero, Gianni Pantuso & Antonio Russo. (2016) A headlight on liquid biopsies: a challenging tool for breast cancer management. Tumor Biology 37:4, pages 4263-4273.
Crossref
Veronica Ferrucci, Iolanda Boffa, Gina De Masi & Massimo Zollo. (2015) Natural compounds for pediatric cancer treatment. Naunyn-Schmiedeberg's Archives of Pharmacology 389:2, pages 131-149.
Crossref
Bhavneet Bhinder, Jeni P. Mahida, Glorymar Ibáñez, Kathryn Champ, Christophe Antczak & Hakim Djaballah. 2015. Recent Advances in Retinoblastoma Treatment. Recent Advances in Retinoblastoma Treatment 73 84 .
Faya M. Millimouno, Jia Dong, Liu Yang, Jiang Li & Xiaomeng Li. (2014) Targeting Apoptosis Pathways in Cancer and Perspectives with Natural Compounds from Mother Nature. Cancer Prevention Research 7:11, pages 1081-1107.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.